| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain, Postoperative | 24 | 2021 | 146 | 5.000 |
Why?
|
| Analgesics, Opioid | 15 | 2021 | 109 | 3.020 |
Why?
|
| Analgesics | 12 | 2019 | 48 | 2.450 |
Why?
|
| Analgesia | 7 | 2021 | 18 | 2.070 |
Why?
|
| Pain Management | 10 | 2021 | 74 | 2.070 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 338 | 1.940 |
Why?
|
| Arthroplasty, Replacement, Knee | 8 | 2021 | 264 | 1.840 |
Why?
|
| Anesthetics, Local | 8 | 2016 | 45 | 1.720 |
Why?
|
| Morphine | 10 | 2021 | 40 | 1.700 |
Why?
|
| Nerve Block | 7 | 2020 | 33 | 1.680 |
Why?
|
| Dexamethasone | 5 | 2016 | 22 | 1.520 |
Why?
|
| Chronic Pain | 9 | 2022 | 63 | 1.500 |
Why?
|
| Bupivacaine | 4 | 2016 | 27 | 1.460 |
Why?
|
| Ketamine | 5 | 2019 | 18 | 1.440 |
Why?
|
| Complex Regional Pain Syndromes | 5 | 2020 | 11 | 1.400 |
Why?
|
| Low Back Pain | 9 | 2021 | 69 | 1.110 |
Why?
|
| Motor Activity | 5 | 2017 | 175 | 1.090 |
Why?
|
| Animals | 21 | 2020 | 2092 | 1.060 |
Why?
|
| Ketorolac | 3 | 2016 | 8 | 1.040 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2016 | 39 | 1.020 |
Why?
|
| Humans | 48 | 2022 | 12240 | 0.960 |
Why?
|
| Pain Measurement | 20 | 2018 | 211 | 0.930 |
Why?
|
| Arthroplasty, Replacement, Hip | 6 | 2014 | 349 | 0.900 |
Why?
|
| Male | 39 | 2021 | 6815 | 0.880 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 37 | 0.830 |
Why?
|
| Female | 30 | 2021 | 6974 | 0.800 |
Why?
|
| Surgical Wound Infection | 3 | 2018 | 38 | 0.780 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2011 | 16 | 0.760 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2017 | 142 | 0.740 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2018 | 225 | 0.730 |
Why?
|
| Arthralgia | 3 | 2018 | 56 | 0.700 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 31 | 0.690 |
Why?
|
| Acute Pain | 2 | 2018 | 9 | 0.690 |
Why?
|
| Osteoarthritis, Knee | 2 | 2021 | 169 | 0.680 |
Why?
|
| Middle Aged | 23 | 2020 | 4043 | 0.670 |
Why?
|
| Mice | 6 | 2020 | 760 | 0.660 |
Why?
|
| Treatment Outcome | 13 | 2021 | 1478 | 0.660 |
Why?
|
| Zygapophyseal Joint | 3 | 2020 | 18 | 0.650 |
Why?
|
| Sciatic Nerve | 4 | 2016 | 15 | 0.630 |
Why?
|
| Clonidine | 4 | 2016 | 8 | 0.630 |
Why?
|
| Spine | 3 | 2021 | 50 | 0.620 |
Why?
|
| Lumbar Vertebrae | 3 | 2018 | 182 | 0.620 |
Why?
|
| Abdominal Muscles | 1 | 2020 | 5 | 0.620 |
Why?
|
| Metformin | 1 | 2020 | 9 | 0.620 |
Why?
|
| Edema | 1 | 2020 | 15 | 0.610 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 14 | 0.610 |
Why?
|
| Anesthesia, Conduction | 6 | 2021 | 15 | 0.610 |
Why?
|
| Antiemetics | 1 | 2020 | 11 | 0.610 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2017 | 11 | 0.610 |
Why?
|
| Neuralgia | 2 | 2019 | 8 | 0.600 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2019 | 6 | 0.600 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 28 | 0.600 |
Why?
|
| Electrodes, Implanted | 2 | 2018 | 8 | 0.590 |
Why?
|
| Pain Threshold | 4 | 2021 | 14 | 0.570 |
Why?
|
| Vancomycin | 1 | 2018 | 18 | 0.560 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2016 | 9 | 0.550 |
Why?
|
| Prospective Studies | 9 | 2021 | 817 | 0.550 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 205 | 0.540 |
Why?
|
| Glucocorticoids | 2 | 2016 | 35 | 0.500 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 6 | 2010 | 15 | 0.500 |
Why?
|
| Laparotomy | 1 | 2016 | 9 | 0.490 |
Why?
|
| Buprenorphine | 1 | 2016 | 1 | 0.490 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 207 | 0.490 |
Why?
|
| Cytokines | 3 | 2015 | 107 | 0.480 |
Why?
|
| Joints | 1 | 2016 | 43 | 0.470 |
Why?
|
| Time Factors | 8 | 2018 | 695 | 0.450 |
Why?
|
| Cervical Vertebrae | 2 | 2014 | 122 | 0.450 |
Why?
|
| Aged | 14 | 2020 | 4000 | 0.450 |
Why?
|
| Epidural Space | 2 | 2014 | 13 | 0.440 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2014 | 5 | 0.430 |
Why?
|
| Steroids | 1 | 2014 | 12 | 0.430 |
Why?
|
| Spouses | 4 | 2019 | 17 | 0.420 |
Why?
|
| Random Allocation | 3 | 2020 | 59 | 0.420 |
Why?
|
| Spinal Fusion | 1 | 2017 | 176 | 0.410 |
Why?
|
| Catastrophization | 3 | 2021 | 11 | 0.410 |
Why?
|
| Models, Animal | 2 | 2016 | 74 | 0.400 |
Why?
|
| Ultrasonography, Interventional | 2 | 2014 | 36 | 0.380 |
Why?
|
| Fentanyl | 2 | 2003 | 14 | 0.380 |
Why?
|
| Magnesium | 2 | 2003 | 34 | 0.370 |
Why?
|
| Hip Joint | 3 | 2012 | 136 | 0.370 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 84 | 0.360 |
Why?
|
| Substance P | 1 | 2011 | 6 | 0.350 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2011 | 7 | 0.350 |
Why?
|
| Norepinephrine | 1 | 2011 | 19 | 0.350 |
Why?
|
| Glutamic Acid | 1 | 2011 | 15 | 0.350 |
Why?
|
| Sulfones | 2 | 2010 | 12 | 0.340 |
Why?
|
| Blood Patch, Epidural | 2 | 2008 | 6 | 0.330 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 7 | 0.330 |
Why?
|
| Anesthesia | 1 | 2010 | 19 | 0.320 |
Why?
|
| Wound Healing | 1 | 2010 | 55 | 0.320 |
Why?
|
| Rats | 10 | 2018 | 407 | 0.310 |
Why?
|
| Analgesia, Epidural | 2 | 2017 | 25 | 0.310 |
Why?
|
| Behavior, Animal | 4 | 2016 | 32 | 0.310 |
Why?
|
| Denervation | 3 | 2020 | 15 | 0.310 |
Why?
|
| Interpersonal Relations | 3 | 2019 | 48 | 0.310 |
Why?
|
| Dinoprostone | 2 | 2007 | 12 | 0.300 |
Why?
|
| Adult | 12 | 2020 | 3557 | 0.290 |
Why?
|
| Hematoma, Subdural, Intracranial | 1 | 2008 | 1 | 0.290 |
Why?
|
| Subdural Effusion | 1 | 2008 | 5 | 0.280 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2015 | 14 | 0.280 |
Why?
|
| Anesthesiologists | 2 | 2018 | 4 | 0.280 |
Why?
|
| Societies, Medical | 2 | 2018 | 48 | 0.270 |
Why?
|
| Catheter Ablation | 2 | 2018 | 21 | 0.270 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 20 | 0.270 |
Why?
|
| Injections | 3 | 2016 | 22 | 0.260 |
Why?
|
| Lactones | 1 | 2007 | 3 | 0.260 |
Why?
|
| Cohort Studies | 3 | 2020 | 827 | 0.260 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 22 | 0.260 |
Why?
|
| Double-Blind Method | 6 | 2021 | 166 | 0.260 |
Why?
|
| Preoperative Care | 1 | 2007 | 42 | 0.260 |
Why?
|
| Length of Stay | 3 | 2020 | 126 | 0.250 |
Why?
|
| Drug Combinations | 2 | 2016 | 17 | 0.250 |
Why?
|
| Interleukins | 1 | 2006 | 13 | 0.240 |
Why?
|
| Central Nervous System | 1 | 2006 | 29 | 0.230 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 143 | 0.230 |
Why?
|
| Retrospective Studies | 4 | 2020 | 1467 | 0.230 |
Why?
|
| Injections, Spinal | 4 | 2018 | 16 | 0.220 |
Why?
|
| Postoperative Complications | 1 | 2007 | 385 | 0.210 |
Why?
|
| Exploratory Behavior | 2 | 2016 | 6 | 0.190 |
Why?
|
| Pregabalin | 3 | 2011 | 8 | 0.190 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 76 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 116 | 0.180 |
Why?
|
| Spinal Cord | 3 | 2012 | 46 | 0.180 |
Why?
|
| Analgesia, Obstetrical | 1 | 2002 | 22 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 46 | 0.180 |
Why?
|
| Spinal Cord Stimulation | 1 | 2022 | 3 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 68 | 0.170 |
Why?
|
| Ontario | 1 | 2021 | 9 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 128 | 0.160 |
Why?
|
| Adaptation, Psychological | 2 | 2015 | 83 | 0.160 |
Why?
|
| Physicians | 1 | 2021 | 43 | 0.160 |
Why?
|
| Anesthesia, Epidural | 2 | 2011 | 11 | 0.160 |
Why?
|
| Postoperative Period | 4 | 2019 | 118 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2018 | 42 | 0.160 |
Why?
|
| Tibial Fractures | 1 | 2020 | 4 | 0.160 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 78 | 0.160 |
Why?
|
| Risk Factors | 3 | 2018 | 1049 | 0.150 |
Why?
|
| Lidocaine | 3 | 2012 | 17 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2018 | 214 | 0.150 |
Why?
|
| Chicago | 2 | 2011 | 453 | 0.150 |
Why?
|
| Illness Behavior | 1 | 2019 | 3 | 0.150 |
Why?
|
| Uncertainty | 1 | 2019 | 7 | 0.150 |
Why?
|
| Social Perception | 1 | 2019 | 4 | 0.150 |
Why?
|
| Consensus | 4 | 2022 | 47 | 0.150 |
Why?
|
| Musculoskeletal Pain | 1 | 2019 | 13 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2020 | 95 | 0.140 |
Why?
|
| Oxycodone | 1 | 2019 | 4 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 12 | 0.140 |
Why?
|
| Rodentia | 1 | 2018 | 3 | 0.140 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2009 | 9 | 0.140 |
Why?
|
| Hostility | 1 | 2018 | 9 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 79 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2018 | 55 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 19 | 0.140 |
Why?
|
| Betamethasone | 1 | 2018 | 2 | 0.130 |
Why?
|
| Sacroiliac Joint | 1 | 2018 | 5 | 0.130 |
Why?
|
| Triamcinolone Acetonide | 1 | 2018 | 5 | 0.130 |
Why?
|
| United States | 5 | 2021 | 989 | 0.130 |
Why?
|
| Pain | 3 | 2021 | 193 | 0.130 |
Why?
|
| Perioperative Care | 1 | 2018 | 24 | 0.130 |
Why?
|
| Methylprednisolone | 1 | 2018 | 10 | 0.130 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2009 | 14 | 0.130 |
Why?
|
| Spinal Puncture | 2 | 2011 | 12 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 2152 | 0.130 |
Why?
|
| Up-Regulation | 3 | 2007 | 89 | 0.130 |
Why?
|
| Amides | 2 | 2010 | 9 | 0.130 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2009 | 7 | 0.130 |
Why?
|
| Knee Joint | 2 | 2018 | 284 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 55 | 0.130 |
Why?
|
| Ganglia, Spinal | 1 | 2017 | 35 | 0.130 |
Why?
|
| Research Design | 1 | 2018 | 79 | 0.130 |
Why?
|
| Mood Disorders | 1 | 2017 | 13 | 0.130 |
Why?
|
| Hyperalgesia | 1 | 2017 | 33 | 0.130 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 111 | 0.130 |
Why?
|
| Wound Closure Techniques | 1 | 2016 | 4 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 17 | 0.120 |
Why?
|
| Pseudomonas Infections | 1 | 2016 | 17 | 0.120 |
Why?
|
| Oxygen | 1 | 2016 | 26 | 0.120 |
Why?
|
| Quality of Life | 1 | 2018 | 261 | 0.120 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2015 | 1 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 2015 | 2 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2015 | 29 | 0.110 |
Why?
|
| Patient Selection | 2 | 2014 | 111 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 6 | 0.110 |
Why?
|
| Social Behavior | 1 | 2015 | 38 | 0.110 |
Why?
|
| Insulin | 1 | 2015 | 41 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2015 | 53 | 0.110 |
Why?
|
| Ibuprofen | 1 | 2015 | 5 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2017 | 118 | 0.110 |
Why?
|
| Infusions, Intravenous | 4 | 2018 | 31 | 0.110 |
Why?
|
| Headache Disorders | 1 | 2014 | 2 | 0.110 |
Why?
|
| Anger | 1 | 2014 | 9 | 0.110 |
Why?
|
| Migraine Disorders | 1 | 2014 | 5 | 0.110 |
Why?
|
| Arousal | 1 | 2014 | 27 | 0.110 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 81 | 0.100 |
Why?
|
| Pain Clinics | 1 | 2014 | 4 | 0.100 |
Why?
|
| Anesthesia, General | 1 | 2014 | 13 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 14 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2004 | 28 | 0.100 |
Why?
|
| Triage | 1 | 2012 | 9 | 0.090 |
Why?
|
| Pregnancy | 2 | 2003 | 193 | 0.090 |
Why?
|
| Perioperative Period | 1 | 2011 | 6 | 0.090 |
Why?
|
| Interleukin-6 | 2 | 2015 | 48 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2009 | 186 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2011 | 8 | 0.080 |
Why?
|
| Catheterization | 1 | 2011 | 23 | 0.080 |
Why?
|
| Warfarin | 1 | 2011 | 11 | 0.080 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2011 | 37 | 0.080 |
Why?
|
| Intracranial Hypotension | 2 | 2008 | 4 | 0.080 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 9 | 0.080 |
Why?
|
| Preoperative Period | 1 | 2010 | 34 | 0.080 |
Why?
|
| Diabetic Neuropathies | 1 | 2010 | 3 | 0.080 |
Why?
|
| Psychometrics | 1 | 2010 | 95 | 0.080 |
Why?
|
| Skin | 1 | 2010 | 73 | 0.080 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2007 | 5 | 0.080 |
Why?
|
| Amines | 2 | 2007 | 6 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 20 | 0.080 |
Why?
|
| Drug Synergism | 3 | 2004 | 20 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 423 | 0.070 |
Why?
|
| Reoperation | 1 | 2010 | 366 | 0.070 |
Why?
|
| Recurrence | 1 | 2008 | 126 | 0.070 |
Why?
|
| Range of Motion, Articular | 1 | 2009 | 278 | 0.070 |
Why?
|
| Sleep | 1 | 2009 | 155 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2018 | 24 | 0.070 |
Why?
|
| Pain, Intractable | 1 | 2007 | 7 | 0.060 |
Why?
|
| Terrorism | 1 | 2007 | 7 | 0.060 |
Why?
|
| Neostigmine | 1 | 2007 | 3 | 0.060 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 9 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 258 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2007 | 90 | 0.060 |
Why?
|
| Incidence | 1 | 2007 | 338 | 0.060 |
Why?
|
| Indans | 2 | 2004 | 5 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 23 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2006 | 13 | 0.060 |
Why?
|
| Arachnoiditis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cauda Equina | 1 | 2005 | 4 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 726 | 0.060 |
Why?
|
| Self Report | 2 | 2017 | 94 | 0.060 |
Why?
|
| Epinephrine | 3 | 2012 | 17 | 0.060 |
Why?
|
| Ion Channels | 1 | 2004 | 130 | 0.050 |
Why?
|
| Fetal Monitoring | 1 | 2002 | 3 | 0.050 |
Why?
|
| Heart Rate, Fetal | 1 | 2002 | 3 | 0.050 |
Why?
|
| Pruritus | 1 | 2002 | 5 | 0.050 |
Why?
|
| Intracranial Pressure | 1 | 2002 | 5 | 0.050 |
Why?
|
| Heart Rate | 1 | 2002 | 55 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2002 | 99 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 18 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 400 | 0.040 |
Why?
|
| Radio Waves | 1 | 2020 | 5 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 151 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2014 | 105 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 324 | 0.040 |
Why?
|
| Exercise | 1 | 2021 | 233 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 105 | 0.040 |
Why?
|
| Medical Records | 1 | 2018 | 13 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 9 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 23 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 18 | 0.030 |
Why?
|
| Thigh | 1 | 2017 | 15 | 0.030 |
Why?
|
| Injections, Intra-Articular | 1 | 2018 | 31 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 165 | 0.030 |
Why?
|
| Naloxone | 1 | 2017 | 2 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2017 | 3 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 13 | 0.030 |
Why?
|
| Walking | 1 | 2017 | 108 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 132 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 118 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 58 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 2 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 10 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2015 | 15 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2015 | 3 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 26 | 0.030 |
Why?
|
| Empathy | 1 | 2015 | 18 | 0.030 |
Why?
|
| Streptozocin | 1 | 2015 | 1 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2015 | 37 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 42 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2015 | 31 | 0.030 |
Why?
|
| Flatulence | 1 | 2015 | 1 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 98 | 0.030 |
Why?
|
| Facial Pain | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2014 | 4 | 0.030 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2014 | 8 | 0.030 |
Why?
|
| Deep Brain Stimulation | 1 | 2014 | 15 | 0.030 |
Why?
|
| Electric Stimulation Therapy | 1 | 2014 | 18 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 22 | 0.030 |
Why?
|
| Neurosurgery | 1 | 2014 | 18 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 294 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 2 | 2004 | 18 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 201 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 179 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 863 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 218 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 229 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 9 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 182 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 363 | 0.020 |
Why?
|
| Sensation | 1 | 2010 | 5 | 0.020 |
Why?
|
| Adrenergic Agonists | 1 | 2010 | 4 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 19 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 2010 | 3 | 0.020 |
Why?
|
| Absorption | 1 | 2010 | 3 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 4 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 7 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 18 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 39 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2010 | 156 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 252 | 0.020 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2007 | 2 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 22 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2007 | 84 | 0.020 |
Why?
|
| Vocalization, Animal | 1 | 2005 | 2 | 0.010 |
Why?
|
| Tissue Adhesions | 1 | 2005 | 7 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2007 | 134 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 558 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2005 | 28 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2004 | 1 | 0.010 |
Why?
|
| Colforsin | 1 | 2004 | 8 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 16 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 117 | 0.010 |
Why?
|
| Depression | 1 | 2005 | 229 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cisterna Magna | 1 | 2002 | 2 | 0.010 |
Why?
|
| Injections, Epidural | 1 | 2002 | 8 | 0.010 |
Why?
|